Colin Farlow cofounded Serotiny, a Bay Area biotech focused on designing therapeutic multi-domain proteins for gene and cell therapies. Colin earned his JD from University of Wisconsin Law School and started Serotiny to apply scalable technologies to gene and cell therapy discovery. Serotiny strategically partnered with leading biotech and Pharma, including Johnson & Johnson, which led to the company’s acquisition of Serotiny.